Vonoprazan and amoxicillin (VA) dual therapy as a mainstream Helicobacter pylori regimen has gained momentum worldwide, but the optimum dosages remain unclear. We aimed to compare the efficacy and safety of VAdual therapy with 2g amoxicillin or 3g amoxicillin, and to assess the short-term effects of therapy on the gut microbiota and antibiotic resistome. We conducted an open-label, non-inferiority randomised controlled trial at 12centres in China. Individuals infected with Hpylori, aged 18-70years, and without previous eradication therapy were recruited. Participants were randomly assigned at a 1:1 ratio (block size of six) to receive vonoprazan (20 mg twice a day) with either low-dose amoxicillin (1 g twice a day; LVA therapy) or high-dose amoxicillin (1 g three times a day; HVA therapy) for 14days. Gastric biopsies were collected before treatment for detection of antibiotic resistance. Stool samples were collected at baseline, week 2, and week 8-10for shotgun metagenomic sequencing. The primary outcome was the eradication rate of Hpylori, assessed by 13C urea breath test, in both intention-to-treat and per-protocol analyses. Secondary outcomes were adverse events, adherence, antibiotic resistance, and alterations to the gut microbiota and antibiotic resistome. The margin used to establish non-inferiority was -0·10. The trial was registered with ClinicalTrials.gov, NCT05649709. Between Feb 13, 2023, and Jan 25, 2024, 504patients (204 [40%] male and 300 [60%] female; mean age 43years [SD 13]) were randomly assigned to LVA therapy or HVA therapy (n=252in each group). No infections were resistant to amoxicillin. The Hpylori eradication rate was 85·3% (215 of 252; 95% CI 80·4to 89·2) in the LVA group and 86·5% (218 of 252; 81·7to 90·2) in the HVA group in the intention-to-treat analysis (p=0·70) and 88·8% (213of240; 84·1to 92·2) and 92·4% (218 of 236; 88·3to 95·1), respectively, in the per-protocol analysis (p=0·18). Theefficacy of LVA was non-inferior to HVA in the intention-to-treat analysis (risk difference -1·2%, 95% CI -7·3 to4·9, p=0·0022) and the per-protocol analysis (-3·6%, -9·0to 1·7, p=0·0085). 31 (12%) patients in the LVA group and43 (17%) patients in the HVA group reported adverse events. Adherence to therapy was 97% in the LVA group and 96% in the HVA group. The diversity of gut microbiota decreased after treatment but was restored to baseline at week 8-10in both groups. The abundance of beta-lactam-related resistance genes was increased at week 2after treatment, and was restored to pretreatment level at week 8-10for the LVA group but not the HVA group. LVA dual therapy was effective and non-inferior to HVA dual therapy as first-line treatment of Hpylori infection and showed a non-lasting effect on the abundance of beta-lactam-related resistance genes. High amoxicillin dosage (eg, 3g per day) is not required to achieve high cure rates with vonoprazan dual therapy. National Natural Science Foundation of China, Project for Academic and Technical Leaders of Major Disciplines in Jiangxi Province, and Key Research and Development Program of Jiangxi Province.
Read full abstract